CTT1057
Prostate Cancer
Not Specified (Likely Clinical)Active
Key Facts
Indication
Prostate Cancer
Phase
Not Specified (Likely Clinical)
Status
Active
Company
About Cancer Targeted Technology
Cancer Targeted Technology is a private, clinical-stage biotech developing a pipeline of small molecule theranostics for prostate cancer. Its lead programs include a PSMA-targeted PET imaging agent (CTT1057) and a radiotherapeutic (CTT1403), with an IND already filed for the latter. The company operates a platform-based business model, is pre-revenue, and has secured non-dilutive grant funding, including a recent $2.4M Fast Track grant, to advance its targeted drug conjugate programs.
View full company profileTherapeutic Areas
Other Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO442 | Aptevo Therapeutics | Preclinical |
| APVO452 | Aptevo Therapeutics | Discovery |
| BIO 300 | Humanetics Corp. | Not Specified |
| Opaganib | RedHill Biopharma | Phase 2 |
| MagSense™ PSMA Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| Leronlimab | CytoDyn | Preclinical |
| CROES Registry | AngioDynamics | Post-Market Registry |
| Cannabics® PRST-33 | CNBX Pharmaceuticals | Discovery |
| HDP-103 | Heidelberg Pharma | Preclinical |
| ENV105 | Kairos Pharma | Phase 2 |
| AI for Prostate Cancer | Invenio Imaging | Research |